I’m pleased to share Mayo Clinic has announced a strategic collaboration with @Microsoft to develop and deploy a frontier AI model designed specifically for healthcare. Read more: newsnetwork.mayoclinic.org/d…

Brilliant discussant slide from @CalaisJeremie putting into context the results from AcTION and CONV01-alpha with PSMAddition and VISION @urotoday #ASCO26

Exciting work on EV-based biomarkers in advanced prostate cancer treated with Lu-177 PSMA, spearheaded by @AJangMD @MayoCancerCare @MayoUrology

Mayo Clinic Urology was honored to host visiting professor Dr. Hashim Ahmed for a discussion on advances in prostate cancer screening, precision diagnosis, and focal therapy. #ProstateCancer #FocalTherapy @imperialcollege @LondonProstate1 @SBoorjian @DerekLomas

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial (Study Protocol) bjui-journals.onlinelibrary.… BRIO is a prospective randomized trial evaluating whether immediate salvage radiotherapy (SRT) ☢️ improves outcomes versus observation with delayed image-guided treatment in men with biochemical recurrence after radical prostatectomy who have negative mpMRI and PSMA-PET/CT imaging. The study will enroll 312 patients with PSA 🧪 0.2–1.5 ng/mL and assess distant recurrence-free survival, quality of life, adverse effects, and biomarker development to clarify optimal management of imaging-negative recurrent #ProstateCancer after surgery overall @DrStish @JakeOrmeMDPhD @vidit_sharma_ @JackAndrewsMD @flscientist @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

What a day it has been!!! @AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment? Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!

Dr. Olivier De Jong from Utrecht University with an outstanding talk on EV engineering to allow gene editing in recipient cells. #ISEV2026

Our talented collaborator Dr. Ishwor Thapa, bioinformatician and data scientist at UNO, presenting an important comparative analysis of total and small RNAseq for EV biomarker discovery. #ISEV2026

Dr. Marca Wauben takes the stage to talk about the relationship between EV cargo and function. #ISEV2026

Dr. Rubia Noori, postdoc in our lab, chairing the session on Diagnostics/Prognostics biomarkers #ISEV2026

Opening ceremony of #ISEV2026 annual meeting!

Uta Erdbruegger presenting the current status of EV-based biomarkers and translational challenges #ISEV2026

Kicking of #ISEV2026 in San Juan (PR) with the Education Day. Great way to get up to speed on the fundamentals of extracellular vesicles (EVs).

We were honored to host Dr. Michael Blute today for a lecture on surgical management of tumor thrombus in RCC. Key insights on operative strategy and multidisciplinary care underscored opportunities to improve outcomes in complex cases.

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: nejm.org/doi/full/10.1056/NE…

Long-term marrow toxicity: Rates and risk factors. Presentation by Daniel Childs, MD @MayoClinic. #PSMA26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/41xmVYG @PSMAconference #2026PSMAandBeyond

Best Poster award for Albert Jang 💪

Albert Jang pitching our ongoing work on ctDNA and EVs for predicting response to Lutetium-PSMA @PSMAconference @MayoUrology @MayoCancerCare Great collaborative team including @aadel_chaudhuri @JakeOrmeMDPhD @sartor_oliver